WO2002012261A1 - Dérivés d'avermectine - Google Patents
Dérivés d'avermectine Download PDFInfo
- Publication number
- WO2002012261A1 WO2002012261A1 PCT/JP2001/006802 JP0106802W WO0212261A1 WO 2002012261 A1 WO2002012261 A1 WO 2002012261A1 JP 0106802 W JP0106802 W JP 0106802W WO 0212261 A1 WO0212261 A1 WO 0212261A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- lower alkyl
- mixture
- solution
- Prior art date
Links
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical class C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 178
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 50
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 38
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 20
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 17
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 239000003096 antiparasitic agent Substances 0.000 claims description 6
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 229940125687 antiparasitic agent Drugs 0.000 claims description 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 3
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 230000002141 anti-parasite Effects 0.000 abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 7
- 239000001257 hydrogen Substances 0.000 abstract description 4
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 169
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 108
- 239000000203 mixture Substances 0.000 description 80
- 239000002904 solvent Substances 0.000 description 79
- 239000000243 solution Substances 0.000 description 67
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- -1 1-piperazinyl group Chemical group 0.000 description 38
- 239000012043 crude product Substances 0.000 description 38
- 238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 37
- 230000002829 reductive effect Effects 0.000 description 36
- 239000011734 sodium Substances 0.000 description 34
- 238000002360 preparation method Methods 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 29
- 238000005481 NMR spectroscopy Methods 0.000 description 29
- 239000010410 layer Substances 0.000 description 29
- 230000036961 partial effect Effects 0.000 description 29
- 238000010898 silica gel chromatography Methods 0.000 description 28
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 26
- 235000017557 sodium bicarbonate Nutrition 0.000 description 25
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 23
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000007864 aqueous solution Substances 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 18
- RRZXIRBKKLTSOM-UHFFFAOYSA-N avermectin B1a Natural products C1=CC(C)C(C(C)CC)OC11OC(CC=C(C)C(OC2OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C2)C(C)C=CC=C2C3(C(C(=O)O4)C=C(C)C(O)C3OC2)O)CC4C1 RRZXIRBKKLTSOM-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 239000002994 raw material Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 238000010828 elution Methods 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 125000005103 alkyl silyl group Chemical group 0.000 description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- CWGATOJEFAKFBK-UHFFFAOYSA-N Ac-(E)-8-Tridecen-1-ol Natural products C1C(O)C(C)C(C(C)CC)OC11OC(CC=C(C)C(OC2OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C2)C(C)C=CC=C2C3(C(C(=O)O4)C=C(C)C(O)C3OC2)O)CC4C1 CWGATOJEFAKFBK-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 241001672739 Artemia salina Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- SHURRSUZDBDBMX-JLSLGBNPSA-N avermectin B2a Natural products CC[C@H](C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](CC=C(/C)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)C=CC=C6/OC[C@@H]7[C@H](O)C(=C[C@@H](C(=O)O3)[C@]67O)C)O2)C[C@@H](O)[C@@H]1C SHURRSUZDBDBMX-JLSLGBNPSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 6
- 241000244206 Nematoda Species 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CWGATOJEFAKFBK-PDVFGPFMSA-N 5-o-demethyl-22,23-dihydro-23-hydroxy-(13r,23s)-avermectin a1a Chemical compound C1[C@H](O)[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 CWGATOJEFAKFBK-PDVFGPFMSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940125833 compound 23 Drugs 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 3
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940125807 compound 37 Drugs 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229960002418 ivermectin Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Chemical class 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241001468227 Streptomyces avermitilis Species 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000033 alkoxyamino group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
- PBTHJVDBCFJQGG-UHFFFAOYSA-N methyl azide Chemical group CN=[N+]=[N-] PBTHJVDBCFJQGG-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- GWSNVTCOTFANCA-UHFFFAOYSA-N (4,6-dioxo-1,3,2-dioxazinan-2-ium-2-ylidene)azanide Chemical compound [N-]=[N+]1OC(=O)CC(=O)O1 GWSNVTCOTFANCA-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- PXXBOKDQFUVPFZ-UHFFFAOYSA-N 2-cyano-2-diazonio-1-ethoxyethenolate Chemical compound CCOC(=O)C(C#N)=[N+]=[N-] PXXBOKDQFUVPFZ-UHFFFAOYSA-N 0.000 description 1
- DYCIOVIEGYZBJP-UHFFFAOYSA-N 2-diazonio-1-ethoxy-2-phenylethenolate Chemical compound CCOC(=O)C(=[N+]=[N-])C1=CC=CC=C1 DYCIOVIEGYZBJP-UHFFFAOYSA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 241000238426 Anostraca Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- YGRFXPCHZBRUKP-UHFFFAOYSA-N Methoxamine hydrochloride Chemical compound Cl.COC1=CC=C(OC)C(C(O)C(C)N)=C1 YGRFXPCHZBRUKP-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000133262 Nauplius Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241001466077 Salina Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical class OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229960004269 methoxamine hydrochloride Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical compound [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- ITDJKCJYYAQMRO-UHFFFAOYSA-L rhodium(2+);diacetate Chemical compound [Rh+2].CC([O-])=O.CC([O-])=O ITDJKCJYYAQMRO-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Definitions
- the present invention, c relates avermectin derivatives having antiparasitic activity
- Evermectin is an antiparasitic antibiotic and Streptomyces evermitilis
- ⁇ Streptomyces avermitilis is an antibiotic produced mainly by four components (A1a,
- A2a, Bla, B2a are known, and among them, avermectin B1a
- An object of the present invention is to provide an avermectin derivative having antiparasitic activity. ⁇
- the present inventors have synthesized various derivatives using avermectin B1a, ivermectin or avermectin B2a as a raw material in order to find an avermectin derivative having higher antiparasitic activity. As a result, they succeeded in obtaining a derivative having high antiparasitic activity represented by the following general formula (I), and completed the present invention.
- R 2 represents a hydroxyl group, a lower alkoxyl group or a tri-lower alkylsilyloxy group
- R 2 and the carbon atom at the 5-position are a double bond
- R 2 is a carbon atom at the 5-position
- R 2 is a carbon atom at the 5-position
- ⁇ —C ( NOH) ⁇
- R 3 represents a hydroxyl group or a tri-lower alkylsilyloxy group>
- a compound or a salt thereof in which R 2 is a hydroxyl group is preferred.
- the present invention provides a medicament containing the compound represented by the above general formula (I) or a physiologically acceptable salt thereof as an active ingredient.
- the medicament can be administered to mammals, including humans, as an antiparasitic agent.
- the present invention provides a method for administering a therapeutically effective amount of a compound represented by the above general formula (I) or a physiologically acceptable salt thereof to mammals including humans. .
- the compound represented by the general formula (I) may be referred to as a compound (I).
- the lower alkyl group may be any of linear, branched, cyclic, or a combination thereof having 1 to 8 carbon atoms, and preferably a linear alkyl group having 1 to 8 carbon atoms. And a branched or branched alkyl group.
- lower alkyl groups include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclopropylmethyl, cyclobutyl, pentyl Group, hexyl group, heptyl group, and octyl group.
- the lower alkyl moiety in a functional group having a lower alkyl moiety such as a lower alkoxyl group, a lower alkylcarboxy group, a lower alkoxycarbonyl group or a tri-lower alkylsilyloxy group is also used. Synonymous with lower alkyl.
- Each lower alkyl moiety in the tri-lower alkylsilyloxy group may be the same or different.
- the alkylene portion of the arylalkyloxy group represented by R 5 is preferably a group obtained by removing one hydrogen atom from the lower alkyl group.
- Examples of the lower alkenyl moiety in the lower alkenyloxycarbonyl group include a linear or branched alkenyl group having 2 to 6 carbon atoms, such as a butyl group, an aryl group, a methacryl group, a butenyl group, and a pentenyl group. And a hexenyl group.
- the number of double bonds present in the alkenyl group is not particularly limited, but is preferably one.
- the heterocyclic group may be either an aromatic heterocyclic group or an aliphatic heterocyclic group.
- aromatic heterocyclic group for example, a 5- or 6-membered monocyclic aromatic heterocyclic group (the monocyclic aromatic heterocyclic group is selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom And at least one heteroatom).
- the aliphatic heterocyclic group for example, a 5- or 6-membered monocyclic aliphatic heterocyclic group (the monocyclic aliphatic heterocyclic group is selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom And at least one heteroatom). More specifically, for example, Examples include a ligininole group, a tetrahydrofuryl group, and a tetrahydroviranyl group.
- the nitrogen-containing heterocyclic group formed together with the P-contacting nitrogen atom includes a morpholino group, a thiomorpholino group, a piperidino group, a 1-piperazinyl group, a 1-pyrrolidinyl group, and the like. Of these, a morpholino group or a piperidino group is preferred.
- aryl group examples include a phenyl group and a naphthyl group.
- arylalkyloxy group represented by R 5 contains one or more heteroatoms
- a 5- or 6-membered monocyclic aromatic heterocyclic group where The monocyclic aromatic heterocyclic group includes at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom. More specifically, such aryl groups include, for example, pyridyl, pyrrolyl, furyl, chenyl, thiazolyl, pyradiel, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, or oxazolyl And the like. Of these, a furyl group is preferred.
- the type and number of substituents on the substituted lower alkyl are not particularly limited, but are preferably 1 to 3 hydroxyl groups, halogen atoms (in the present specification, when a "halogen atom" is referred to, a fluorine atom, a chlorine atom, A bromine atom or an iodine atom,), an amino group, a mono-lower alkylamino group, a lower alkanoylamino group, an aryl group, a monocyclic aromatic heterocyclic group (such as those exemplified above), Lower alkanoyloxy group, azido group, substituted or unsubstituted arylsulfonyloxy group (substituted arylsulfonyloxy group is a lower alkyl group as defined above), lower alkylsulfonyloxy group A hydroxyamino group, a mono-lower alkoxyamino group, a heterocyclic group (the heterocyclic group
- the heterocyclic moiety may be substituted with a halogen atom (the halogen atom is the same as the halogen atom) or a lower alkoxycarbonyl group ⁇ , or a heterocyclic oxy group (tetrahydropi And a carboxyl group, a lower alkoxycarbonyl group, a cyano group and the like (in these, a mono-lower alkoxyamino group, a lower alkoxycarbonyl group, a lower alkylsulfonyloxy group,
- the lower alkyl portion of the lower alkylamino group, the lower alkylaminoyl group, and the lower alkylaminoyloxy group are the same as the lower alkyl group, and the aryl portion of the aryl group and the
- examples of the substituted lower alkyl group include a hydroxymethyl group, a bromomethyl group, an odomethynole group, an azidomethyl group, an aminomethyl group, and a p-toluenesulfonyloxymethyl group.
- two substituents on the lower alkyl group include two lower alkoxycarbonyl groups (the lower alkoxycarbol group is the same as described above).
- the substituted lower alkyl group is preferably a methyl group.
- the type and number of substituents of the substituted aryl group are not particularly limited, but preferably include 1 to 5 -toro, amino, hydroxyl, or halogen atoms.
- the salt of compound (I) is not particularly limited, but a physiologically acceptable salt is preferred.
- Physiologically acceptable salts include acid addition salts, metal salts, ammonium salts, and organic amine addition salts.
- the acid addition salt include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate, and organic acid salts such as acetate, maleate, fumarate, and citrate.
- the metal salt include an alkali metal salt such as a sodium salt and a potassium salt, an alkaline earth metal salt such as a magnesium salt and a calcium salt, an aluminum salt, and a zinc salt.
- ammonium salt an ammonium salt or a tetramethylammonium salt is used.
- the organic amine addition salt include addition salts such as morpholine and piperidine.
- Evermectin B1a which is a raw material of the avermectin derivative disclosed in the present invention, is a compound collected from a culture of Streptomyces avermitilis, and is a known compound (JP-A-3-74397, JP-A-3-74397). 3-254678, US Pat. No. 5,206,155).
- 5-O-tri-lower alkylsilyl-7-O-tri-lower alkylsilyl avermectin B 1a used as an intermediate in synthesizing compound (I) is prepared from avermectin B 1a as a raw material.
- the compound can be synthesized by the method described in Journal of Medicinal Chemistry (J. Med. Chem.), Vol. 25, 658-663 (1982) or a method analogous thereto.
- it can be produced by subjecting the 5-position hydroxyl group of avermectin B1a to tri-lower alkylsilylation, followed by performing tri-lower-alkyl silylich on the 7-position hydroxyl group.
- 5-0-tri-lower alkylsilyl-7- ⁇ -tri-lower alkylsilylyl velmectin which is used as an intermediate in the synthesis of compound (I), is capable of converting the 5-position hydroxyl group of ivermectin to a tri-group. It can be produced by performing tri-lower alkylsilylation of the hydroxyl group at the 7-position after lower alkylsilyl iridescence.
- 5-0-tri-lower alkylsilyl-7-O-tri-lower alkylsilyl avermectin B 2a used as an intermediate in synthesizing the compound (I) is a 5-position of avermectin B 2a
- the defined groups change under the conditions of the method or are inappropriate for carrying out the method, introduction and removal of protecting groups commonly used in organic synthetic chemistry. Separation methods [eg, Protective Groups in Organic Synthesis, written by TW Greene, John Wiley & Sons In (John Wiley & Sons In) 1981
- the target compound can be obtained.
- R 1 is a lower alkoxycarbonyl group
- Compound (I) can be produced.
- the compound (I) wherein R 1 is a carboxyl group can be produced by treating this compound with a base such as alcoholic hydroxylating lime. Manufacturing method 2
- the compound (I) in which R 1 is a carboxyl group obtained in the production method 1 is reacted with a cyclic amine compound (such as piperazine or morpholine) in the presence of a condensing agent, so that R 1 is -CON (R 6 )
- a condensing agent such as piperazine or morpholine
- R 1 is -CON (R 6 )
- Compound (I) which is (R 7 ) wherein R 6 and R 7 together with an adjacent nitrogen atom form a nitrogen-containing complex ring group
- the condensing agent include 1-ethyl-13- (3-dimethylaminopropyl) carbodiimide (WSC I) hydrochloride, 1,3-dicyclohexyl carbodiimide and the like.
- a compound (I) in which R 1 is a carboxyl group is referred to as arylalkyl alcohol (an aryl group may contain one or more heteroatoms as ring-constituting atoms).
- R 1 gar COR 5a wherein, R 5 a represents a ⁇ Li Lumpur alkyl O alkoxy group, ⁇ Li Ichiru groups one or more of the Compound (I), which may contain a terrorist atom as a ring-constituting atom.
- R 1 obtained in Production method 1 is a carboxyl group or a lower alkoxycarbonyl group.
- the compound (I) wherein R 1 is a formyl group can be produced by reducing the compound (I).
- As the reducing agent sodium borohydride, lithium aluminum hydride, diisobutylaluminum hydride, or the like is used.
- the obtained aldehyde compound is reacted with a compound represented by H 2 N_OR 4 (wherein R 4 has the same meaning as described above) to convert it into an oxime compound (hydroxym compound or alkoxym compound). can do.
- the compound (I) in which R 1 is a carboxyl group or a lower alkoxycarbonyl group obtained in the production method 1 is treated with a more powerful reducing agent to obtain a compound (1) in which R 1 is a hydroxymethyl group.
- a more powerful reducing agent can be manufactured.
- the reducing agent lithium triethylborohydride (super hydride) or the like can be used.
- (I) can be produced.
- a compound that is an R4Sp_aminophenyl group can be produced.
- the reduction is carried out, for example, by catalytic reduction in the presence of a palladium carbon catalyst.
- R 1 is! After deprotection at the 5- and 7-positions of compound (I), which is a 12-trophenyl group, a reduction reaction is performed after deprotection according to Production Method 9 described below, and R 1 is a p-aminophenyl group.
- a compound in which the 5-position and the 7-position are 'hydroxyls can be produced.
- a compound (I) in which R 1 is a hydroxymethyl group, and another compound (I) can be manufactured.
- R 1 is a hydroxymethyl group compound (I), by reaction with ⁇ reel sulfo loose black Li de and substituted or unsubstituted replacement in the presence of a base, ⁇ reel sulfonyl R 1 is a substituted or unsubstituted O carboxymethyl It is possible to produce the compound (I) which is a methyl group.
- R 1 is a hydroxymethyl group arsenide Dorokishiru group (I), in Rukoto be halogenated, can R 1 to produce a compound which is a halogenated methyl group (I).
- the halogenation conditions include a reaction with triphenylphosphine / carbon tetrabromide in the presence of a base, and a reaction with triphenylphosphine / iodine in the presence of a base.
- the compound (I) ′ in which R 1 is a methyl azide group can be produced by azidating the compound (I) in which Ri is a methyl halide group.
- Examples of the Azig conditions include a reaction with an allylic azide such as sodium azide or azide amide in an polar solvent.
- the compound (I) in which R 1 is an aminomethyl group can be produced.
- the reduction conditions include reduction using a reduction catalyst in the presence of a hydrogen source such as hydrogen gas or hydrazine, reduction using triphenylphosphine, and the like, which are used in a conventional manner.
- Compound (I) in which R 1 is a lower alkanoylaminomethyl group can be produced by subjecting compound (I) in which R 1 is an aminomethyl group to a lower alkanoyl group.
- the lower alkanoylich method includes a method of reacting a compound (I) in which R 1 is an aminomethyl group with a halogenated lower alkyl group, and a method of reacting a compound (I) in which R 1 is an aminomethyl group with an acid anhydride. And the like.
- Compound (I) in which Ri is a methyl halide group may be converted to HN in the presence of a base, if necessary.
- R 1 is —CH 2 NR 6 R 7 (wherein R 6 and R 7 are each
- R 6 and R 7 are each
- the compound (I) having the same meaning as described above can be produced. Manufacturing method 6.
- 5-0-Tri-lower alkylsilyl-yl 7- ⁇ -trialkyl lower alkylsilyl methine B 1a is reacted with an alkyl derivative of diazoacetate having a substituent such as getyl diazomalonate, ethyl diazophenylacetate, and ethyl diazocyanoacetate.
- R 1 is a lower alkoxycarbonyl group
- R 1 a is a lower alkoxycarbonyl group (the lower alkyl moiety of the lower alkoxycarbonyl group but it may also be substituted with a heterocyclic group)
- compounds which are Shiano group or Ariru group (I) can be produced.
- R 1 is lower alkoxycarbonyl group obtained in the above, R 1 a is lower alkoxy carbonyl (lower alkyl moiety of said lower alkoxycarbonyl group may be substitution in the heterocyclic group), Shiano group or Ariru With respect to the compound (I) which is a group, the 4 "-position substituent can be converted, for example, as follows.
- Compound R 1 ⁇ Pi R 1 a is a lower alkoxycarbonyl group, R 1 is a lower alkoxy force Ruponiru group compound R 1 a is Shiano group, or R 1 is a lower alkoxycarbonyl - a le radical R 1 the a compound is Ariru group, by subjecting to a hydrolysis condition (Arco one Le water- oxidation force Riumu treatment with a base such as such), compound R 1 ⁇ Pi R 1 a is carboxyl radical, R 1 compound force Rupokishiru a group R la is Shiano group, and R 1 is a carboxyl group R 1 a can be produced a compound which is Ariru group.
- a hydrolysis condition Arco one Le water- oxidation force Riumu treatment with a base such as such
- compound R 1 ⁇ Pi R 1 a is carboxyl radical
- R 1 compound force Rupokishiru a group R la is Shiano group
- R 1 is a carboxy
- 5-O-tri-lower alkylsilyl 7-O-tri-lower alkylsilyl avermectin B 1a in which R 1 is a lower alkenyloxycarbyl group B 1a and 5--O-tri-lower alkyl in which R 1 is a cyano group Silyl-7-O-tri-lower alkylsilyl evermectin B1a can be produced according to Production method 1.
- O—tri-lower alkylsilyl avermectin B 1 a is a compound in which R 1 is a formyl group. It can be produced from tri-lower alkylsilyl 7-O-tri-lower alkylsilyl avermectin B 1a and H 2 N—NH—C ⁇ NH 2 or a salt thereof (eg, an acid addition salt).
- R 1 is a butyl group substituted with a lower alkenyloxycarbonyl group.
- 5--1-tri-lower alkylsilyl 7-O-tri-lower alkylsilyl avermectin B 1a R 1 is a formyl group 5-O-tri-lower alkylsilyl-lu 7-O-tri-lower-alkylsilyl avermectin B 1a is combined with an appropriate Wittig reagent (for example, a Witig reagent prepared from aryl acetylethyl phosphonoacetate). It can be produced by reacting.
- an appropriate Wittig reagent for example, a Witig reagent prepared from aryl acetylethyl phosphonoacetate. It can be produced by reacting.
- R 1 is —CO—S—CH 2 —CH 2 _NH—CO—R x (where R x is as defined above) 5—O—tri-lower alkylsilyl 7—0—tri-lower alkyl
- the silyl avermectin B 1a is obtained by converting 5—O—tri-lower alkylsilyl-1 7-O—tri-lower alkylsilyl avermectin B 1a, in which R 1 is a lipoxyl group, into HS—CH 2 —CH 2 —NH— CO—R x (wherein R x has the same meaning as described above).
- the mono-lower alkyl silyl avermectin B1a is subjected to appropriate deprotection conditions (deprotection with acid, in the presence of a metal catalyst such as tetrakistriphenyl phosphonopalladium, a hydrogen source such as sodium borohydride, hydrogen or hydrazine). Deprotection). Manufacturing method 8
- (-OH) —evermectin B 2a (following formula) as a raw material the 5-position hydroxyl group is converted into a tri-lower alkylsilyl, followed by a selective oxidation reaction at the 23-position hydroxyl group, followed by a 7-position hydroxyl group
- the compound can be produced by performing the same reaction as in the above production methods 1 to 7 using the obtained compound as a raw material by performing the tri-lower alkylsilylation.
- the compound (I) in which one X; ⁇ Y— is one CH 2 —CH 2 — is a compound of 5—O—tri-lower alkylsilyl-17-—one obtained in Reference Examples and the like. It can be produced by performing the same reaction as in the above production methods 1 to 7 using tri-lower alkylsilylsilyl bermectin as a raw material.
- one X Y- is one CH 2 - C (wherein, R 1 3 a represents a hydroxyl group)
- the compound can be produced by using the obtained compound as a raw material and performing the same reaction as in the above Production Methods 1 to 7.
- inert solvent tetrahydrofuran, jeti / lethenole, benzene, tonolene, pyridine, isopropyl acetate or the like can be used alone or in combination.
- desilylating agent hydrogen fluoride, hydrochloric acid, hydrogen bromide can be used.
- Sulfuric acid, or a hydrogen fluoride pyridine complex can be used alone or in combination.
- the tri-lower alkylsilyloxy group at the 5-position and / or 7-position may be converted to a hydroxyl group depending on the reaction conditions when performing the functional group conversion at other positions.
- the method described above is a representative example of the method for producing the compound (I), and the method for producing the compound (I) is not limited thereto.
- the compounds of the present invention can also be produced by other production methods, and the above-described methods can be appropriately combined or, if necessary, carried out with appropriate modifications. It will be readily understood by those skilled in the art that the compound '(I) can also be obtained.
- Compound (I) can also be obtained by appropriately combining functional group conversion methods usually used in the field of synthetic organic chemistry.
- compound (I) in which R 2 is a methoxy group is prepared by converting the hydroxyl group of the corresponding compound in which R 2 is a hydroxyl group into a conventional method. It can be produced by more methylation.
- the compound (I) in which R 2 is another lower alkoxyl group can be produced by lower alkylating the hydroxyl group of the corresponding compound in which R 2 is a hydroxyl group by a conventional method.
- Purification of the target compound in the above production method can be carried out by appropriately combining methods commonly used in organic synthetic chemistry, for example, filtration, extraction, washing, drying, concentration, crystallization, various types of chromatography, and the like. Further, the intermediate can be subjected to the next reaction without purification.
- Compound (I) can exist as isomers such as positional isomers, geometric isomers, tautomers, or optical isomers, but all possible isomers and any ratios of the isomers are possible.
- the mixtures according to the present invention are also included in the present invention.
- the compound when a bond of a functional group substituted on a carbon atom or a nitrogen atom forming a double bond is indicated by a wavy line, the compound is an E-form, a Z-form, or a mixture thereof. Which means any of
- compound (I) when it is desired to obtain a salt of compound (I), when compound (I) is obtained in the form of a salt, it may be purified as it is, and when obtained in the free form, it may be dissolved or suspended in an appropriate solvent. What is necessary is just to make it turbid, add an acid or a base, form a salt, isolate and purify.
- the compound (I) and its salts can be used in the form of adducts (hydrates or solvates) with water or various solvents. These adducts, which may exist in form, are also included in the present invention. Furthermore, any crystal form is included in the scope of the present invention.
- OTBDMS represents tert- Bed chill butyldimethylsilyl O carboxylate (OS i (CH 3) 2 C (CH 3) 3) and, OTMS trimethyl silyl O carboxymethyl (OS i (CH 3) 3 ).
- the active ingredient of the medicament of the present invention is selected from the group consisting of a compound represented by the general formula (I) in free form, a physiologically acceptable salt thereof, and a hydrate and solvate thereof.
- One or more of the selected substances can be used. Any mixture of isomers or isomers in pure form may be used.
- the medicament of the present invention is usually provided in the form of a pharmaceutical composition containing one or more pharmaceutical additives and the above substance as an active ingredient.
- the route of administration is not particularly limited, and is administered orally using tablets, granules, capsules, syrups, powders, etc., or parenterally by injection, rectal administration, transmucosal administration, or other means. Can be administered. Pharmaceutical forms suitable for oral or parenteral administration are well known to those skilled in the art, and those skilled in the art can appropriately select additives for pharmaceutical preparations suitable for the production of the preparation.
- the medicament of the present invention is applicable to various parasitic diseases, and the type of the parasite is not particularly limited.
- the medicament of the present invention is applicable to humans or non-human mammals.
- the composition When applied to mammals other than humans, the composition may be administered as a pharmaceutical composition, but the pharmaceutical composition or the above-mentioned active ingredient may be incorporated into feed as such.
- Solution A used in the following examples is a solution obtained by mixing hydrogen fluoride pyridine complex (10 ml), pyridine (6 ml) and tetrahydrofuran (12 m) and storing the mixture in a polypropylene container at -10 ° C or lower. .
- the raw material compound used in the following examples, 5- ⁇ _tert-butyldimethylsilyl-17-O-trimethylsilylevermectin B 1a was prepared by using avermectin B 1a as a raw material.
- Medicinal chemistry J. Med. Chem.), Vol. 25, 658-663 (1982).
- 5-0-tert-butyldimethylsilyl 7-O-trimethylsilylevermectin Bla (259 mg) was dissolved in getyl ether (2.5 ml), and p -nitrobenzylbutaid mid (110 mg), diisopropyl ester Tilamine ( ⁇ ) and silver trifluoromethanesulfonate (137 mg) were added, and the mixture was stirred at room temperature under a nitrogen atmosphere for 5 hours. After adding an aqueous solution of sodium hydrogen carbonate, the mixture was extracted with getyl ether. The getyl ether layer was dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain a crude product.
- This was purified by silica gel gel chromatography (eluting with a developing solvent: chloroform / Z methanol 50/1) to obtain 0.24 g (yield: 100%) of the desired product.
- Escherichia coli peracil-required mutant strain
- Escherichia coli seed medium supplemented with a small amount of peracyl and cultured with shaking at 27 ° C for 1 day.
- elegans was sufficiently grown, subcultured in a Petri dish in which Escherichia coli was grown, and kept at 20 ° C to grow C. elegans. Since the lifespan of the nematodes is about 2 weeks, they were subcultured every week, and 3-5 days after planting, the plants that grew on the whole petri dish were used for the experiments.
- Buffer for Artemia Salina Tris (0.24%), sodium chloride (2.57%), magnesium chloride (0.47%), potassium chloride (0.07%), sodium carbonate Lium (0.02%), magnesium sulfate (0.64%) and calcium chloride (0.02%)
- Solution A was made up of sodium salt (0.3%), Bacto-agar (DIFCO, 1.7%), Bacto-peptone (DIF CO, 0.5%) and yeast extract (DIF CO, 1.
- Solution B is a solution of cholesterol (0.5%) dissolved in ethanol '.
- Solution C is a solution of calcium chloride (13.9%) dissolved in distilled water.
- Solution D is a solution of magnesium sulfate heptahydrate (30.8%) dissolved in distilled water.
- Solution E is a solution of KH 2 P0 4 (13. 54% ) and K 2 HP0 4 and (4. 45%) in distilled water.
- Solution A 100 ml
- solution B 0.1 ml
- solution C 0.05 ml
- solution D 0 ⁇ 1 ml
- solution E 2.5 ml
- mixing at a ratio (no pH adjustment) 60
- An agar medium for nematode propagation was prepared by dispensing 10 ml each into a 15 mm Petri dish.
- DI FCO Dissolve Batato tryptone
- sodium chloride 0.55%
- SI GMA peracil
- a test compound solution (solvent: methanol) is placed in a 96-well microplate, and the solvent is distilled off with a vacuum pump. Then, 250 ⁇ L of Atsey medium [Atsey medium is distilled water with sodium hydrogencarbonate (7.5 mM), Potassium chloride (7.5 mM), calcium chloride 2 Hydrate (7.5 mM) and magnesium sulfate heptahydrate (7.5 mM) were dissolved and lecithin (0.01%) was added, and the mixture was added for 15 minutes using a microplate mixer. Shake. In this, Senobudeteis elegance was used to rub the surface of the agar lightly with a toothpick, and several of them were added.
- the evaluation results were represented by the following four-level indices of 0 to 3.
- Table 5 shows the results.
- the numerical value of each compound in Table 5 is the minimum concentration (MIC: minimum inhibitory concentration) for each of the above methods to be used as the index 2 (or the index 3) for Senobudetes elegans and Artemia salina.
- MIC minimum inhibitory concentration
- CENO and AS are abbreviated, respectively, to Senobudétesjelegans and Artemis Salina.
- an avermectin derivative having antiparasitic activity or a salt thereof is provided.
- the above derivative or a salt thereof is useful as an active ingredient of an antiparasitic agent.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002518235A JPWO2002012261A1 (ja) | 2000-08-09 | 2001-08-08 | エバーメクチン誘導体 |
CA002418968A CA2418968C (en) | 2000-08-09 | 2001-08-08 | Avermectin derivatives |
US10/343,980 US7144866B2 (en) | 2000-08-09 | 2001-08-08 | Avermectin derivatives |
AU2001277712A AU2001277712A1 (en) | 2000-08-09 | 2001-08-08 | Avermectin derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-240987 | 2000-08-09 | ||
JP2000240987 | 2000-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002012261A1 true WO2002012261A1 (fr) | 2002-02-14 |
Family
ID=18732257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/006802 WO2002012261A1 (fr) | 2000-08-09 | 2001-08-08 | Dérivés d'avermectine |
Country Status (5)
Country | Link |
---|---|
US (1) | US7144866B2 (ja) |
JP (2) | JPWO2002012261A1 (ja) |
AU (1) | AU2001277712A1 (ja) |
CA (1) | CA2418968C (ja) |
WO (1) | WO2002012261A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0229804D0 (en) | 2002-12-20 | 2003-01-29 | Syngenta Participations Ag | Avermection b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substituent in the 4"- or 4'-position |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0456509A1 (en) * | 1990-05-11 | 1991-11-13 | Merck & Co. Inc. | Derivatives of 3' - and 3"-0-desmethyl avermectin compounds |
EP0506331A1 (en) * | 1991-03-28 | 1992-09-30 | Merck & Co. Inc. | 4"-and 4'-alkylthio-avermectin derivatives |
WO1995004746A1 (en) * | 1993-08-04 | 1995-02-16 | Pfizer Limited | Antiparasitic agents |
WO1995022552A1 (en) * | 1994-02-16 | 1995-08-24 | Pfizer Limited | Antiparasitic agents |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4200581A (en) * | 1978-08-04 | 1980-04-29 | Merck & Co., Inc. | Alkyl derivatives of C-076 compounds |
US4427663A (en) * | 1982-03-16 | 1984-01-24 | Merck & Co., Inc. | 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof |
US4833168A (en) | 1986-10-03 | 1989-05-23 | Merck & Co., Inc. | Avermectin reformatsky adducts |
FR2619087B1 (fr) * | 1987-08-03 | 1990-03-23 | Icp Sa | Deflecteur de raidissement de coin pour emballage de groupement |
US4895837A (en) * | 1988-01-29 | 1990-01-23 | Merck & Co., Inc. | Avermectin derivatives |
US4906619A (en) | 1988-07-22 | 1990-03-06 | Merck & Co., Inc. | Alkyl avermectin derivatives |
US5030622A (en) | 1989-06-02 | 1991-07-09 | Merck & Co., Inc. | Avermectin derivatives |
JP2888586B2 (ja) * | 1990-03-05 | 1999-05-10 | 社団法人北里研究所 | エバーメクチンの特定成分を選択生産するための微生物およびその選択的製造法 |
CA2052860A1 (en) | 1990-10-11 | 1992-04-12 | Thomas L. Shih | Avermectin degradation products and derivatives |
US5229415A (en) * | 1992-03-24 | 1993-07-20 | Merck & Co., Inc. | Alkylthio alkyl avermectins are active antiparasitic agents |
JPH0633273A (ja) | 1992-07-16 | 1994-02-08 | Asahi Chem Ind Co Ltd | Alcの埋込金属部材用の防錆剤 |
GB9312154D0 (en) | 1993-06-12 | 1993-07-28 | Pfizer Ltd | Antiparasitic agents |
US5437451A (en) * | 1993-10-01 | 1995-08-01 | Dd Stud, Inc. | Draw stud poker-type card game |
US5897436A (en) * | 1996-06-14 | 1999-04-27 | Ptt, Llc | Modified poker card game |
US6416407B1 (en) * | 1998-11-16 | 2002-07-09 | Travis Carrico | Multi-draw poker |
MXPA01007963A (es) * | 1999-02-09 | 2004-01-29 | Kitasato Inst | Derivados de evermectin. |
-
2001
- 2001-08-08 JP JP2002518235A patent/JPWO2002012261A1/ja active Pending
- 2001-08-08 CA CA002418968A patent/CA2418968C/en not_active Expired - Fee Related
- 2001-08-08 WO PCT/JP2001/006802 patent/WO2002012261A1/ja active Application Filing
- 2001-08-08 US US10/343,980 patent/US7144866B2/en not_active Expired - Fee Related
- 2001-08-08 AU AU2001277712A patent/AU2001277712A1/en not_active Abandoned
-
2012
- 2012-05-14 JP JP2012110510A patent/JP2012176971A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0456509A1 (en) * | 1990-05-11 | 1991-11-13 | Merck & Co. Inc. | Derivatives of 3' - and 3"-0-desmethyl avermectin compounds |
EP0506331A1 (en) * | 1991-03-28 | 1992-09-30 | Merck & Co. Inc. | 4"-and 4'-alkylthio-avermectin derivatives |
WO1995004746A1 (en) * | 1993-08-04 | 1995-02-16 | Pfizer Limited | Antiparasitic agents |
WO1995022552A1 (en) * | 1994-02-16 | 1995-08-24 | Pfizer Limited | Antiparasitic agents |
Also Published As
Publication number | Publication date |
---|---|
AU2001277712A1 (en) | 2002-02-18 |
US20040018993A1 (en) | 2004-01-29 |
JP2012176971A (ja) | 2012-09-13 |
CA2418968A1 (en) | 2003-02-07 |
JPWO2002012261A1 (ja) | 2004-01-15 |
CA2418968C (en) | 2009-11-24 |
US7144866B2 (en) | 2006-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5439464B2 (ja) | エバーメクチン誘導体 | |
NZ582536A (en) | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors | |
JP4832645B2 (ja) | エバーメクチン誘導体 | |
JPH05255342A (ja) | 4a−置換アベルメクチン誘導体 | |
US11661406B2 (en) | Method for producing intermediate useful for synthesis of SGLT inhibitor | |
JPWO2004106352A1 (ja) | アルドヘキソピラノース中間体の製造法 | |
JP2837957B2 (ja) | 駆虫薬 | |
WO2002012261A1 (fr) | Dérivés d'avermectine | |
JP4691101B2 (ja) | 1−α−ハロ−2,2−ジフルオロ−2−デオキシ−D−リボフラノース誘導体及びその製造方法 | |
KR100556335B1 (ko) | 6알-(3,6-디데옥시-엘-아라비노-헥소피라노실옥시)헵타노익산, 그 제조방법 및 그를 포함하는 장기휴면 유발효과 | |
EP2376512B1 (fr) | Derives de morphine-6-glucuronide, leur preparation et leur application en therapeutique | |
WO1993016090A1 (en) | Amphotericin b derivative | |
KR960011778B1 (ko) | 신규한 결정성 세팔로스포린 유도체의 제조방법 | |
EP1165581B1 (fr) | Procede de preparation du 4'-demethyl -4'- phosphate-2",3" - bis pentafluorophenoxyacetyl -4",6" -ethylidene - beta-d-glucoside d'epipodophyllotoxine, et de ses sels | |
JP2006008626A (ja) | フラボン誘導体の製造法ならびにフラボン誘導体およびそれを含む医薬組成物 | |
KR20120051328A (ko) | 신규한 뉴클레오시드 유도체 | |
JP2002275136A (ja) | 不飽和カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤 | |
JPS6345679B2 (ja) | ||
JPH024228B2 (ja) | ||
JPH09143190A (ja) | アリール c−グリコシル化合物の製造方法及びそのための試薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002518235 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2418968 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10343980 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |